Martine Rothblatt (UTHR) uses 10b5-1 plan to exercise 8,000 options
Rhea-AI Filing Summary
United Therapeutics director and Chairperson & CEO Martine A. Rothblatt reported option exercises and subsequent sales under a pre-arranged 10b5-1 trading plan entered on 05/02/2025. On 10/03/2025 and 10/06/2025 she exercised a total of 8,000 stock options with a $120.26 exercise price and sold multiple blocks of shares at weighted-average prices ranging roughly from $445 to $451. Following the reported transactions she directly beneficially owned 4,130 shares and indirectly held large positions through family trusts and spouse (e.g., 324,518, 258,117, 45,596, 15,962). The 10b5-1 plan covers a tranche of 294,000 options expiring 03/15/2026 or ending by 12/31/2025, whichever is earlier. The filing states multiple trades were executed at specified price ranges and offers to provide transaction details on request.
Positive
- Use of a pre-arranged 10b5-1 plan provides an affirmative defense and reduces timing concerns
- Large retained indirect holdings (e.g., 324,518 and 258,117) indicate continued substantial insider alignment
Negative
- Significant share sales executed at ~ $445–$451 reduce direct insider-held common stock to 4,130 shares
- Options tranche of 294,000 remains and expires 03/15/2026, creating potential for further sales before expiration
Insights
Insider exercised 8,000 options and sold shares under a 10b5-1 plan.
The reported activity shows an exercise of 8,000 stock options at a $120.26 strike and multiple sales executed at weighted-average prices between roughly $445 and $451. The trades were carried out under a pre-arranged 10b5-1 plan dated 05/02/2025, which is intended to provide an affirmative defense to Rule 10b5-1 concerns.
Principal dependencies are the remaining 294,000 option tranche expiring 03/15/2026 and the plan termination date of 12/31/2025. Watch for additional Form 4 filings if the plan continues or if significant tranches are exhausted before those dates.
Substantial indirect holdings remain through family trusts and spouse.
The reporting person retains concentrated indirect ownership via multiple family trusts and spouse-controlled shares, totaling several hundred thousand shares (e.g., 324,518 and 258,117). Direct ownership after these transactions is small (4,130 shares), while indirect positions represent the bulk of beneficial holdings.
For governance and voting implications, monitor any changes in trust or spouse holdings reported in future filings and note the exercise/sale window tied to options expiring 03/15/2026.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 4,000 | $0.00 | -- |
| Exercise | Common Stock | 4,000 | $120.26 | $481K |
| Sale | Common Stock | 1,000 | $445.24 | $445K |
| Sale | Common Stock | 3,000 | $451.175 | $1.35M |
| Exercise | Stock Option | 4,000 | $0.00 | -- |
| Exercise | Common Stock | 4,000 | $120.26 | $481K |
| Sale | Common Stock | 1,000 | $443.63 | $444K |
| Sale | Common Stock | 1,629 | $445.6121 | $726K |
| Sale | Common Stock | 1,371 | $448.8074 | $615K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025. This plan will continue until the earlier of: (a) exhaustion of a tranche of 294,000 stock options that expire March 15, 2026; or (b) December 31, 2025. This transaction was executed in multiple trades at prices ranging from $445.385 to $445.755. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $448.48 to $449.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $450.555 to $451.485. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
